Viking Global Opportunities Portfolio GP LLC's Net Worth
$1.82 Billion
Who is Viking Global Opportunities Portfolio GP LLC?
Viking Global Opportunities Portfolio GP LLC has an estimated net worth of $1.82 Billion. This is based on reported shares across multiple companies, which include Amylyx Pharmaceuticals, Inc., Adaptive Biotechnologies Corp, Zentalis Pharmaceuticals, Inc., RayzeBio, Inc., Editas Medicine, Inc., Inhibrx, Inc., Arbutus Biopharma Corp, Myovant Sciences Ltd., Roivant Sciences Ltd., PROCEPT BioRobotics Corp, BridgeBio Pharma, Inc., 4D Molecular Therapeutics, Inc., Rallybio Corp, Ginkgo Bioworks Holdings, Inc., APi Group Corp, FIGS, Inc., Urovant Sciences Ltd., Axovant Gene Therapies Ltd., and Frazier Lifesciences Acquisition Corp.
SEC CIK
Viking Global Opportunities Portfolio GP LLC's CIK is 0001629472
Past Insider Trading and Trends
2019 was Viking Global Opportunities Portfolio GP LLC's most active year for acquiring shares with 36 total transactions. Viking Global Opportunities Portfolio GP LLC's most active month to acquire stocks was the month of January. 2022 was Viking Global Opportunities Portfolio GP LLC's most active year for disposing of shares, totalling 22 transactions. Viking Global Opportunities Portfolio GP LLC's most active month to dispose stocks was the month of August. 2019 saw Viking Global Opportunities Portfolio GP LLC paying a total of $116,172,272.92 for 72,849,851 shares, this is the most they've acquired in one year. In 2020 Viking Global Opportunities Portfolio GP LLC cashed out on 10,750,813 shares for a total of $271,743,539.29, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Amylyx Pharmaceuticals, Inc. (AMLX) Snapshot price: $15.51
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -10.26% | -1.40M |
$29.80 | -$41,719,639.31 | 12.24M |
Sep 8 - Sep 9
| |||
Form 4
|
∞
| 7.17M |
$19.00 | $43,700,000.00 | 7.17M |
Jan 11 - Nov 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Adaptive Biotechnologies Corp (ADPT) Snapshot price: $3.575
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -7.46% | -2.50M |
$49.52 | -$123,787,500.00 | 30.99M |
Nov 11
| |||
Form 4
| -12.79% | -4.91M |
$24.98 | -$122,706,039.29 | 33.49M |
Jan 28
| |||
Form 4
| +2,595.20% | 36.98M |
$20.00 |
—
| 38.41M |
Jul 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Zentalis Pharmaceuticals, Inc. (ZNTL) Snapshot price: $11.57
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -11.25% | -500.00K |
$50.50 | -$25,250,000.00 | 3.94M |
Dec 1
| |||
Form 4
| +19.50% | 725K |
$18.00 | $13,050,000.00 | 4.44M |
Apr 7
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
RayzeBio, Inc. (RYZB) Snapshot price: $62.125
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -6.64M |
—
|
—
|
0
|
Feb 26
| |||
Form 4
|
∞
| 6.64M |
$18.00 |
—
| 6.64M |
Sep 19
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Editas Medicine, Inc. (EDIT) Snapshot price: $7.1553
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4/A
|
∞
| 5.46M |
—
|
—
| 5.46M |
Feb 8 - Feb 8
| |||
Form 4
|
∞
| 5.46M |
—
|
—
| 5.46M |
Feb 8 - Feb 8
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |